


10/530667

JC13 Rec'd PCT/PTO 06 APR 2005

V:\GRuffles\wpp286463\New PCT claims.doc

CLAIMS


1. A compound represented by the general formula (I)



Formula I

wherein:

X is the following radical:



L is independently selected from $-\text{C}(\text{R})(\text{R}')-$, $-\text{CO}-$, $-\text{O}-$ or $-\text{NR}'-$

n is zero, one, two, three, four, five, six, seven, eight, nine or ten

R and R' are independently selected from hydrogen, alkyl, aryl, heteroaryl, halo, haloalkyl, alkoxy, hydroxyl, nitro and alkylthio

D is independently selected from $-\text{C}(\text{R}_9)-$, $=\text{C}-$, or $-\text{N}-$

A₁, A₂, A₃, A₄, A₅, A₇, A₈, E and G are independently selected from $-\text{CO}-$, $-\text{C}(\text{R}_{10})(\text{R}_{11})-$, $=\text{C}(\text{R}_{10})-$, $-\text{N}(\text{R}_{12})-$, $=\text{N}-$, $-\text{O}-$, $-\text{S}(\text{O})_t-$


R_1 , R_2 , R_3 , R_4 , R_9 , R_{10} and R_{11} are independently selected from hydrogen, alkyl, alkoxy, hydroxyl, alkylthio, cycloalkyl, haloalkyl, halo, aryl, $-(Z)_n$ -, aryl, heteroaryl, $-O(R_7)$ -, $-C(O)R_7$ -, $-C(O)OR_7$ -, $-S(O)_t$ -, cyano, nitro and mercapto, aryl substituted by alkyl, alkoxy, hydroxy, halo, haloalkyl, nitro or alkylthio; and heteroaryl substituted by alkyl, alkoxy, hydroxy, halo, haloalkyl, nitro or alkylthio

Z is independently selected from $-C(R_7)(R_8)-$ -, $-C(O)-$ -, $-O-$ -, $-C(=NR_7)-$ -, $-S(O)_t$ -, $N(R_7)-$


R_7 and R_8 are independently selected from hydrogen, alkyl, alkoxy, alkylthio, cycloalkyl, haloalkyl, halo, aryl, heteroaryl, cyano, nitro, mercapto, aryl substituted by alkyl, alkoxy, hydroxy, halo, haloalkyl, nitro or alkylthio; and heteroaryl substituted by alkyl, alkoxy, hydroxy, halo, haloalkyl, nitro or alkylthio

t is zero, one or two;

with the exclusion of the following two compounds:



and



2. A compound according to claim 1, wherein X is selected from phthalimide (1,3-dioxo-1,3-dihydro-isoindol-2-yl), indol-2-yl, 1-

indanon-2-yl, benzimidazol-2-yl, indadion-2-yl, indazol-2-yl, benzofuran-2-yl, benzothiophen-2-yl, or benzotriazol-2-yl.

3. A compound according to claim 1 wherein X is phthalimide (1,3-dioxo-1,3-dihydro-isoindol-2-yl) and the cyclic part of formula I represents 9-acridinyl, 1,2,3,4-tetrahydro-acridin-9-yl or 6-chloro, 1,2,3,4-tetrahydro-acridin-9-yl.
4. A compound according to claim 1 which is:
 - 2-[6-(acridin-9-ylamino)-hexyl]-isoindole-1,3-dione (6),
 - 2-[7-(acridin-9-ylamino)-heptyl]-isoindole-1,3-dione (7),
 - 2-[8-(acridin-9-ylamino)-octyl]-isoindole-1,3-dione (8),
 - 2-[9-(acridin-9-ylamino)-nonyl]-isoindole-1,3-dione (9),
 - N-[7-(6-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamino)-heptyl]-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-acetamide (10),
 - N-(3-[[3-(6-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamino)-propyl]-methyl-amino]-propyl)-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-acetamide (11),
 - N-[6-(6-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamino)-hexyl]-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-acetamide (12),
 - 2-[6-(1,2,3,4-Tetrahydro-acridin-9-ylamino)-hexylamino]-indan-1,3-dione (3),
 - 2-[7-(1,2,3,4-Tetrahydro-acridin-9-ylamino)-heptyl]-isoindole-1,3-dione (4), or
 - 2-[8-(1,2,3,4-Tetrahydro-acridin-9-ylamino)-octyl]-isoindole-1,3-dione (5).
5. A compound according to claim 1 wherein X is 1-indanon-2-yl and the cyclic part of formula I represents 1,2,3,4-tetrahydro-acridin-9-yl.

6. A compound according to claim 5 which is:
 - 5,6-Dimethoxy-2-[[7-(1,2,3,4-tetrahydro-acridin-9-ylamino)-heptylamino]-methyl]-indan-1-one (1) or
 - 5,6-Dimethoxy-2-[[6-(1,2,3,4-tetrahydro-acridin-9-ylamino)-hexylamino]-methyl]-indan-1-one (2).
7. A pharmaceutical formulation containing as active ingredient a compound as defined in any of claims 1 to 6.
8. Compound according to any of claims 1 to 6 for use as a medicament
9. Compound according to any of claims 1 to 6 for use in treating cognitive disorders as senile dementia, cerebrovascular dementia, mild cognition impairment, attention deficit disorder, and/or neurodegenerative dementing disease with aberrant protein aggregations as specially Alzheimer's disease, Parkinson disease, ALS, or prion diseases, as Creutzfeldt-Jakob disease or Gerstmann-Straussler-Scheinher disease.
10. Use of a compound according to any of claims 1 to 6 for preparing a medicament.
11. Use of a compound according to any of claims 1 to 6 for the manufacture of a medicament for treating cognitive disorders as senile dementia, cerebrovascular dementia, mild cognition impairment, attention deficit disorder, and/or neurodegenerative dementing disease with aberrant protein aggregations as specially Alzheimer's

disease, Parkinson disease, ALS, or prion diseases, as Creutzfeldt-Jakob disease or Gerstmann-Straussler-Scheinher disease.

12. A method of treating a cognitive disorder, which comprises administering an effective amount of a compound as defined in claim 1.